Joelle Lufkin

1.2k total citations
26 papers, 909 citations indexed

About

Joelle Lufkin is a scholar working on Pharmacology, Rheumatology and Physiology. According to data from OpenAlex, Joelle Lufkin has authored 26 papers receiving a total of 909 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 16 papers in Rheumatology and 6 papers in Physiology. Recurrent topics in Joelle Lufkin's work include Osteoarthritis Treatment and Mechanisms (15 papers), Inflammatory mediators and NSAID effects (13 papers) and Pain Mechanisms and Treatments (6 papers). Joelle Lufkin is often cited by papers focused on Osteoarthritis Treatment and Mechanisms (15 papers), Inflammatory mediators and NSAID effects (13 papers) and Pain Mechanisms and Treatments (6 papers). Joelle Lufkin collaborates with scholars based in United States, United Kingdom and Australia. Joelle Lufkin's co-authors include N. Bodick, Philip G. Conaghan, James R. Johnson, Virginia B. Kraus, Alan Kivitz, Francis Bérenbaum, Stanley Cohen, David J. Hunter, Scott D. Kelley and Michael D. Clayman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Joelle Lufkin

26 papers receiving 889 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joelle Lufkin United States	11	442	224	207	191	112	26	909
Xinzhan Mao China	18	427 1.0×	157 0.7×	482 2.3×	156 0.8×	93 0.8×	52	1.0k
Augustin Latourte France	15	743 1.7×	218 1.0×	363 1.8×	232 1.2×	121 1.1×	52	1.2k
Roxana Coras United States	13	567 1.3×	101 0.5×	398 1.9×	145 0.8×	107 1.0×	26	1.0k
Huizhong Wang China	13	234 0.5×	149 0.7×	302 1.5×	93 0.5×	94 0.8×	39	809
Sonia Nasi Switzerland	15	398 0.9×	86 0.4×	318 1.5×	101 0.5×	86 0.8×	33	784
Yiqing Tao China	23	136 0.3×	446 2.0×	244 1.2×	459 2.4×	64 0.6×	45	1.3k
Jianlin Zhou China	15	151 0.3×	148 0.7×	265 1.3×	78 0.4×	104 0.9×	33	685
Peijian Tong China	19	325 0.7×	82 0.4×	443 2.1×	167 0.9×	95 0.8×	55	868
Zhihong Xu China	14	263 0.6×	330 1.5×	172 0.8×	93 0.5×	43 0.4×	46	730
Alyssa Torres United States	6	442 1.0×	82 0.4×	266 1.3×	128 0.7×	88 0.8×	7	691

Countries citing papers authored by Joelle Lufkin

Since Specialization

Citations

This map shows the geographic impact of Joelle Lufkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joelle Lufkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joelle Lufkin more than expected).

Fields of papers citing papers by Joelle Lufkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joelle Lufkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joelle Lufkin. The network helps show where Joelle Lufkin may publish in the future.

Co-authorship network of co-authors of Joelle Lufkin

This figure shows the co-authorship network connecting the top 25 collaborators of Joelle Lufkin. A scholar is included among the top collaborators of Joelle Lufkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joelle Lufkin. Joelle Lufkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Naing, Aung, Samuel J. Klempner, Sabbir Khan, et al.. (2023). 1033P First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors. Annals of Oncology. 34. S627–S628. 2 indexed citations

Kivitz, Alan, Purvi Mehra, P Hanson, et al.. (2022). A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip Osteoarthritis. Rheumatology and Therapy. 9(2). 679–691. 4 indexed citations

Hanson, P, Alan Kivitz, Purvi Mehra, et al.. (2021). Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized Study. Drugs in R&D. 21(3). 285–293. 4 indexed citations

Ross, Edgar L., Nathaniel P. Katz, Philip G. Conaghan, et al.. (2021). Improved Treatment Effect of Triamcinolone Acetonide Extended-Release in Patients with Concordant Baseline Pain Scores on the Average Daily Pain and Western Ontario and McMaster Universities Osteoarthritis Index Pain Scales. Pain and Therapy. 11(1). 289–302. 4 indexed citations

Kivitz, Alan, P. Mehra, P Hanson, et al.. (2019). Safety and systemic exposure of triamcinolone acetonide following intra-articular injection of triamcinolone acetonide extended-release or standard triamcinolone in patients with hip osteoarthritis. Osteoarthritis and Cartilage. 27. S504–S505. 1 indexed citations

Langworthy, Michael J., Philip G. Conaghan, Alan Kivitz, et al.. (2019). Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis. Advances in Therapy. 36(6). 1398–1411. 29 indexed citations

Kivitz, Alan, Philip G. Conaghan, Amy Çinar, Joelle Lufkin, & Scott D. Kelley. (2019). Rescue Analgesic Medication Use by Patients Treated with Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Randomized Clinical Trials. SHILAP Revista de lepidopterología. 8(2). 271–280. 9 indexed citations

Spitzer, Andrew I., John C. Richmond, Virginia B. Kraus, et al.. (2019). Safety and Efficacy of Repeat Administration of Triamcinolone Acetonide Extended-release in Osteoarthritis of the Knee: A Phase 3b, Open-label Study. Rheumatology and Therapy. 6(1). 109–124. 30 indexed citations

Conaghan, Philip G., George Habib, Robert Manning, et al.. (2018). Triamcinolone acetonide extended-release injectable suspension (TA-ER) is associated with reduced blood glucose elevation vs. standard triamcinolone in type 2 diabetes mellitus patients with knee osteoarthritis: a randomized, blinded, parallel-group study. Osteoarthritis and Cartilage. 26. S230–S230. 3 indexed citations

10.

Russell, Steven J., Philip G. Conaghan, George Habib, et al.. (2018). Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study. Lara D. Veeken. 57(12). 2235–2241. 29 indexed citations

11.

Mehra, P., et al.. (2017). Synovial and systemic pharmacokinetics of triamcinolone acetonide following intra-articular injection of an extended release formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis. Osteoarthritis and Cartilage. 25. S431–S431. 3 indexed citations

12.

Conaghan, Philip G., Vibeke Strand, David J. Hunter, et al.. (2017). An intra-articular, extended release formulation of triamcinolone (FX006) affords clinically relevant improvements in pain and function of knee osteoarthritis: post-hoc pooled analyses of 3 randomized controlled trials. Osteoarthritis and Cartilage. 25. S432–S433. 3 indexed citations

13.

Kraus, Virginia B., Philip G. Conaghan, P. Mehra, et al.. (2017). Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). Osteoarthritis and Cartilage. 26(1). 34–42. 107 indexed citations

14.

Conaghan, Philip G., Stanley Cohen, Joanne M. Jordan, et al.. (2016). Sustained and profound analgesic benefits in people with osteoarthritis of the knee using FX006, an intra-articular extended-release formulation of triamcinolone acetonide: Results from a double-blind, randomized, parallel-group, dose-ranging study. Osteoarthritis and Cartilage. 24. S49–S50. 3 indexed citations

15.

Bodick, N., et al.. (2015). Prolonged joint residency of triamcinolone acetonide after an intra-articular injection of FX006, a sustained release formulation for the treatment of osteoarthritis. Osteoarthritis and Cartilage. 23. A360–A361. 4 indexed citations

16.

Bodick, N., Joelle Lufkin, Anjali S. Kumar, et al.. (2015). An Intra-Articular, Extended-Release Formulation of Triamcinolone Acetonide Prolongs and Amplifies Analgesic Effect in Patients with Osteoarthritis of the Knee. Journal of Bone and Joint Surgery. 97(11). 877–888. 98 indexed citations

17.

Bodick, N., Joelle Lufkin, Anjali S. Kumar, et al.. (2014). Safety and efficacy of FX006 in patients with osteoarthritis of the knee. Osteoarthritis and Cartilage. 22. S376–S377. 2 indexed citations

18.

O’Day, Steven, Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, et al.. (2013). Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. Journal of Clinical Oncology. 31(9). 1211–1218. 236 indexed citations

19.

Bodick, N., et al.. (2013). FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis. Osteoarthritis and Cartilage. 21. S144–S145. 14 indexed citations

20.

Krausz, Sarah, Maria J H Boumans, Daniëlle M. Gerlag, et al.. (2011). Brief Report: A phase IIa, randomized, double‐blind, placebo‐controlled trial of apilimod mesylate, an interleukin‐12/interleukin‐23 inhibitor, in patients with rheumatoid arthritis. Arthritis & Rheumatism. 64(6). 1750–1755. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact